Naltrexone can do both, and which one you experience depends heavily on the dose, the condition being treated, and how long you have been taking it. At standard doses (50 mg daily, prescribed for alcohol or opioid use disorder), naltrexone commonly causes both drowsiness and insomnia. At much lower doses (typically 1–5 mg daily, often called low-dose naltrexone or LDN), some people report a noticeable lift in energy, especially when fatigue is tied to chronic inflammation or an immune-related condition. The picture is genuinely paradoxical, and the research reflects that messiness.
Standard-Dose Naltrexone and the Sleep-Energy Problem
When naltrexone is prescribed at its FDA-approved dose of 50 mg for alcohol use disorder, fatigue-related side effects are among the most frequently reported complaints. A systematic review with meta-analysis of opioid-receptor drugs used in alcohol treatment found that naltrexone significantly increased both somnolence (daytime sleepiness) and insomnia compared with placebo.1PubMed Central. Sleep and the Pharmacotherapy of Alcohol Use Disorder: Unfortunate Bedfellows. A Systematic Review With Meta-Analysis That combination sounds contradictory, but it makes sense if you think of it as the drug disrupting normal sleep architecture: you sleep poorly at night, then feel drowsy during the day. The net result for many people is a general sense of tiredness rather than a feeling of extra energy.
This is the naltrexone experience most clinicians are trained to recognize. Prescribing information for the standard dose lists fatigue, somnolence, and sleep difficulties as common adverse effects. For people taking naltrexone to manage alcohol cravings or to support opioid abstinence, these side effects are often tolerable and tend to lessen over weeks, but they are real and can be discouraging early on. If you search for naltrexone and fatigue, this standard-dose context is what most of the conventional medical literature addresses.
How Low-Dose Naltrexone Flips the Script
Low-dose naltrexone occupies a different pharmacological niche. At doses roughly one-tenth of the standard prescription, naltrexone appears to act less as a straightforward opioid blocker and more as an immune modulator. Research suggests that at low doses, the drug briefly blocks opioid receptors just long enough to trigger a rebound increase in the body’s own endorphin production, while also tamping down inflammatory signaling through pathways involving cytokines like IL-6 and TNF-α, as well as acting as an antagonist at Toll-like receptor 4 (TLR4), a receptor involved in the brain’s inflammatory response.2International Immunopharmacology. Low-dose naltrexone use for the management of post-acute sequelae of COVID-19
That anti-inflammatory activity is the key to understanding why some people feel more energetic on LDN. Conditions characterized by chronic low-grade inflammation or immune dysregulation, such as fibromyalgia, chronic fatigue syndrome (ME/CFS), and long COVID, often produce crushing fatigue as a primary symptom. If LDN dials down the inflammatory load, the fatigue can lift, and the patient experiences that as “more energy.” It is not a stimulant effect in the way caffeine works. It is more like removing a weight the immune system had been placing on the body.
What the Fatigue-Condition Trials Actually Show
The evidence for LDN improving fatigue comes mostly from studies in people who were already profoundly fatigued due to a chronic illness. The results are encouraging but uneven, and the details matter.
In long COVID, the data is among the most favorable. A systematic review and meta-analysis pooling results from pre-post studies found moderate effects for reducing fatigue and improving sleep quality, along with large effects for pain and daily functioning, all in favor of LDN.3PubMed Central. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis A separate pilot study combining LDN at 4.5 mg daily with NAD+ supplementation in 36 patients with persistent post-COVID fatigue found that fatigue scores dropped substantially after 12 weeks, though roughly half the group were classified as responders and half were not.4PubMed Central. Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19 That split is important: even in a condition where LDN seems to help, it does not help everyone equally.
In fibromyalgia, the picture is more mixed on the energy question specifically. A meta-analysis found LDN superior to placebo for alleviating pain, but one well-known randomized crossover trial noted that while LDN improved mood and general life satisfaction, it did not significantly improve fatigue or sleep.5PubMed. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels Systematic reviews of LDN in fibromyalgia have generally found it effective for symptom management overall with a reassuring safety profile, but pain reduction has been the headline result, not fatigue relief.6PubMed Central. The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review If you are taking LDN for fibromyalgia and hoping specifically for more energy, the evidence suggests you are more likely to get pain relief and mood benefits, with fatigue improvement being a bonus that some people experience but others do not.
In ME/CFS, research on LDN is still early but has yielded some mechanistic clues. A study of ME/CFS patients taking LDN at 3–5 mg daily found that the drug appeared to restore certain ion channel functions in natural killer cells, pointing to a specific immune pathway through which LDN might address the underlying biology of the illness rather than just masking symptoms.7PubMed Central. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment Patients in that research reported subjective benefit, but the study focused on cellular mechanisms rather than measuring fatigue outcomes with standardized questionnaires, so the energy-improvement claims rest more on patient reports than on hard outcome data.
Energy Improvements in Other Fatigue-Related Conditions
A narrative review covering LDN use across a range of conditions noted that in an interventional study of 52 patients with a post-infectious disorder, two months of LDN at 1–3 mg daily was associated with significant self-reported improvements in energy, along with recovery, daily activities, pain, concentration, and sleep. In Gulf War Illness, a placebo-controlled crossover trial found that responders to LDN at 4.5 mg daily showed significantly greater improvements in energy and fatigue measures compared with non-responders.8PubMed Central. Low-Dose Naltrexone: What is the Evidence? A Narrative Review The common thread across these conditions is persistent fatigue linked to immune dysfunction or chronic inflammation. When LDN helps, the energy benefit appears to follow from calming an overactive immune response rather than from a direct stimulant action on the nervous system.
There has also been some interest in LDN for people with postural orthostatic tachycardia syndrome (POTS), a condition where fatigue is a prominent symptom. A small case series of six POTS patients treated with LDN found that three reported improvement, two discontinued because they did not notice a benefit, and outcome measures were inconsistent across the group, with some patients improving while others worsened on fatigue scores.9Cureus. Low-Dose Naltrexone Use in Postural Orthostatic Tachycardia Syndrome: A Case Series Six patients is too few to draw any firm conclusions, but the mixed results echo the broader theme: LDN is not a guaranteed energy booster, even in conditions defined by fatigue.
The Early Worsening Period
One pattern that frustrates many new LDN users is a temporary increase in fatigue during the first days or weeks. Reports from patients and clinicians suggest that side effects can be troublesome initially, with increased fatigue and headaches being among the most commonly mentioned.10BMJ Case Reports. Low-dose naltrexone as a treatment for chronic fatigue syndrome The prevailing explanation is that the initial blockade of opioid receptors disrupts the body’s endorphin signaling before the compensatory upregulation kicks in. In plain terms, the drug temporarily takes away some of your feel-good chemistry before the body starts producing more of it.
This startup phase is one reason clinicians who prescribe LDN typically begin at a very low dose, sometimes as low as 0.5 or 1 mg, and increase gradually over several weeks. The goal is to minimize that early dip in energy and mood so the patient sticks with the medication long enough to see whether the longer-term benefits materialize. If you have just started LDN and feel worse before you feel better, that experience is common and does not necessarily mean the drug is wrong for you, but it also does not guarantee that it will eventually help.
Why the Opioid System Matters for Energy and Sleep
The reason naltrexone can affect energy at all is that the endogenous opioid system is deeply woven into the brain’s regulation of sleep, wakefulness, and motivation. Research in animal models has shown that opioid receptors expressed by light-sensitive cells in the retina contribute to the promotion of wakefulness and the inhibition of slow-wave sleep, with endogenous beta-endorphin activating these receptors as part of the circadian system that modulates sleep and wake activity.11Neurobiology of Sleep and Circadian Rhythms. Endogenous opioid signaling in the retina modulates sleep/wake activity in mice When you introduce an opioid receptor blocker like naltrexone, you are interfering with a system that does far more than manage pain. You are also touching the machinery of alertness, motivation, and reward.
At standard doses, that interference can be heavy-handed, which helps explain the sleep disruption and daytime drowsiness. At low doses, the brief blockade followed by a rebound may actually sharpen the system’s responsiveness, contributing to the improved energy some patients report. This is still somewhat speculative, but it provides a plausible biological bridge between the observed effects at different dose ranges.
Genetic Variation and Why Your Response May Differ
One underappreciated factor in how naltrexone affects your energy is genetics. The mu-opioid receptor, naltrexone’s primary target, is encoded by the OPRM1 gene, which has a well-studied variant known as A118G. A systematic review and meta-analysis found that naltrexone-treated patients carrying the G allele of this variant had significantly lower relapse rates in alcohol dependence compared with those carrying only the A allele.12PubMed. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis While that finding is specific to alcohol outcomes rather than energy levels, it illustrates a broader point: people’s opioid receptors are not all wired the same way, and naltrexone binds and acts differently depending on your genetic makeup.
This genetic variability likely extends to energy and fatigue responses as well, though direct research on that link is limited. If you try naltrexone (at any dose) and find that it makes you feel sedated while your friend on the same regimen feels energized, genetics could be a significant part of the explanation. The opioid system is highly individual, and no two people’s endorphin baselines or receptor sensitivities are identical.
Very Low Doses and the Drowsiness Question
An interesting data point comes from research at even lower doses than typical LDN. A double-blind trial evaluating very low-dose naltrexone (0.25 mg) during opioid detoxification found that this dose significantly reduced drowsiness and dysphoric mood compared with controls.13PubMed Central. Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety That finding is in an opioid-dependent population undergoing withdrawal, so it is not directly transferable to someone taking LDN for fatigue. But it reinforces the dose-dependent nature of naltrexone’s effects: at a quarter of a milligram, the drug appeared to reduce sleepiness rather than cause it, which is the opposite direction from the standard-dose experience.
The clinical relevance here is that the relationship between naltrexone dose and energy is not a simple linear one. More drug does not necessarily mean more tiredness, and less drug does not necessarily mean less effect. The opioid system responds to brief, partial blockade differently than it responds to sustained, heavy blockade, and that difference in receptor dynamics is what makes the low-dose and standard-dose experiences so divergent.
Practical Takeaways for People Considering Naltrexone
If you are being prescribed naltrexone at 50 mg for alcohol or opioid use disorder, expect some fatigue and possible sleep disruption, especially in the first few weeks. These side effects are well-documented and tend to improve with time, though they do not disappear entirely for everyone. They are generally considered manageable relative to the benefits of the medication for its intended use.
If you are exploring LDN for a fatigue-related condition, the honest summary of the evidence is that it helps some people and does nothing for others, and predicting which category you will fall into is not yet possible. The conditions with the best supporting data for fatigue improvement are long COVID and post-infectious syndromes. Fibromyalgia patients tend to see pain and mood benefits more consistently than energy benefits. ME/CFS research is promising at a mechanistic level but still thin on large-scale outcome data.
Regardless of dose, a few practical considerations apply:
- Timing matters: Many LDN prescribers recommend taking it at bedtime, partly because the brief opioid blockade happens during sleep and the endorphin rebound occurs in the morning. Some people find that bedtime dosing gives them vivid dreams or disrupted sleep, in which case switching to morning dosing sometimes helps.
- Start low: Gradual dose escalation from 0.5–1 mg up to the target dose of 3–4.5 mg over several weeks reduces the likelihood of that early fatigue dip.
- Give it time: Most clinicians who work with LDN suggest waiting at least 8–12 weeks before judging whether it is helping, because the immune-modulating effects build slowly.
- Track your symptoms: Because the response is so variable, keeping a simple daily log of energy, sleep quality, and pain levels can help you and your prescriber determine whether the drug is doing anything meaningful for you specifically.
The Opioid-Dependent Complication
One population that deserves separate mention is anyone currently taking opioid medications. Naltrexone at any dose blocks opioid receptors, which means it can precipitate withdrawal in someone who has opioids in their system. Precipitated withdrawal is intensely unpleasant and includes symptoms far beyond fatigue, such as severe cramping, vomiting, and agitation. This is not a “side effect” in the usual sense but a dangerous drug interaction. If you are on any opioid medication, including tramadol or certain cough suppressants, naltrexone should not be started without a washout period, and the decision should involve a physician who understands the timing involved.
Even in non-opioid-dependent individuals, the fact that naltrexone blocks the receptor your body uses for its own endorphins means the drug can temporarily dampen the natural reward and motivation circuits. For some people, this manifests not as physical tiredness but as a kind of emotional flatness or reduced motivation, a subtler form of fatigue that does not always show up on standard questionnaire measures but that patients describe consistently in online forums and clinical conversations. This effect is more commonly reported at standard doses and tends to be less of an issue at low doses, though individual experiences vary.
What Online Communities Get Right and Wrong
LDN has a passionate patient advocacy community, and if you search for personal accounts online, you will find many people describing dramatic improvements in energy. Some of those accounts are genuine and consistent with the clinical evidence. But the community sometimes overstates the certainty and universality of LDN’s benefits. A few points worth keeping in mind: the largest and most rigorous studies show that roughly half of participants respond meaningfully, not all of them; the fibromyalgia trial that is frequently cited as proof of LDN’s effectiveness specifically found that fatigue did not improve significantly; and the long COVID data, while encouraging, comes largely from pre-post studies without placebo controls, meaning some improvement could reflect natural recovery over time rather than the drug itself.
Conversely, people in standard-dose naltrexone communities who report persistent fatigue and emotional blunting are describing something real that the clinical literature supports. The challenge for anyone researching this topic online is that the standard-dose and low-dose experiences are so different that they might as well be different drugs, but they share a name. Confusing the two leads to a lot of unnecessary anxiety in both directions: people starting 50 mg for alcohol use disorder worry they will be zombified, and people starting 4.5 mg for fatigue worry they will get the side-effect profile of a completely different dosing regimen.